A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib-Reference-Cited by-同舟云学术

A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib

Published:2019-11 Issue:11 Volume:14 Page:e257-e259
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Sharma Geeta G.^ORCID,Cortinovis Diego,Agustoni Francesco,Arosio Giulia,Villa Matteo,Cordani Nicoletta,Bidoli Paolo,Bisson William H.,Pagni Fabio,Piazza Rocco,Gambacorti-Passerini Carlo,Mologni Luca

Funder

European Union

Italian Association for Cancer Research

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference5 articles.

1. ALK in lung cancer: past, present, and future;Shaw;J Clin Oncol,2013

2. Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer;Gainor;Cancer Discov,2016

3. Clinical utility of cell-free DNA for the detection of ALK fusions and genomic mechanisms of ALK inhibitor resistance in non-small cell lung cancer;McCoach;Clin Cancer Res,2018

4. Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer;Camidge;N Engl J Med,2018

5. Sequential ALK inhibitors can select for lorlatinib-resistant compound ALK mutations in ALK-positive lung cancer;Yoda;Cancer Discov,2018

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. FGFR2 promotes resistance to ALK tyrosine kinase inhibitors and its inhibition acts synergistically with lorlatinib in the treatment of ALK-expressing neuroblastoma;2024-09-10

2. A Review on Anaplastic Lymphoma Kinase (ALK) Rearrangements and Mutations: Implications for Gastric Carcinogenesis and Target Therapy;Current Protein & Peptide Science;2024-09

3. Synergistic Antitumor Effects of 177Lu-Octreotide Combined with an ALK Inhibitor in a High-Risk Neuroblastoma Xenograft Model;Therapeutics;2024-08-07

4. Targeting NRAS via miR-1304-5p or farnesyltransferase inhibition confers sensitivity to ALK inhibitors in ALK-mutant neuroblastoma;Nature Communications;2024-04-23

5. New pan-ALK inhibitor-resistant EML4::ALK mutations detected by liquid biopsy in lung cancer patients;npj Precision Oncology;2024-03-06